- Location
major depressive disorder
"-
Patients with Depression Have Areas of Reduced Cortical Thickness
Jan 23, 2014Patients with depression have areas of reduced cortical thickness, with clear distinctions between those with bipolar disorder and major depressive disorder (MDD), report US researchers. "Cortical thickness may prove to be a useful tool ...
-
Patients with MDD Increased Use of Maladaptive and Decreased Use of Adaptive ER Strategies
Jan 16, 2014By Lucy Piper, Senior medwireNews Reporter Patients with bipolar disorder and major depressive disorder (MDD) have increased use of maladaptive and decreased use of adaptive emotion regulation (ER) strategies, researchers report. ...
Tags: emotion regulation, Larissa Wolkenstein, University of Tübingen
-
BBRF Has Announced The Latest Recipients of Its Narsad Distinguished Investigator Grants
Nov 12, 2013The Brain & Behavior Research Foundation (BBRF) (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of president and CEO Dr Jeffrey Borenstein, has announced the latest ...
Tags: Narsad, BBRF, investigator, award
-
Mylan Has Obtained FDA Approval for sANDA for GSK's WELLBUTRIN XL
Aug 26, 2013Mylan has obtained FDA approval for its supplemental abbreviated new drug application (sANDA) for the generic version of GSK's WELLBUTRIN XL, bupropion hydrochloride extended-release tablets USP (XL), 300mg. Bioequivalence study results ...
Tags: FDA Approval, drug application
-
Naurex Has Announced The Issuance of New US Patent for Partial Agonist
Aug 2, 2013Naurex has announced the issuance of new US patent for selective NMDA receptor partial agonist, GLYX-13, covering methods of treating major depressive disorder through 2030. In a Phase II trial, GLYX-13 demonstrated considerable safety, ...
-
FDA Acceptance of Vortioxetine New Drug Application Filing for Major Depressive disorder
Dec 14, 2012Takeda Global Research & Development Center and Lundbeck have announced the FDA acceptance of vortioxetine new drug application (NDA) filing for major depressive disorder. The companies have also announced the proposal of Brintellix as ...
Tags: FDA, new drug application, NDA
-
Mylan Has Been Sued Jointly by Pfizer,Wyeth Pharmaceutical,Wyeth LLC and PF Prism
Dec 7, 2012Mylan has been sued jointly by Pfizer,Wyeth Pharmaceutical,Wyeth LLC and PF Prism regarding the filing of an abbreviated new drug application (ANDA) with the US food and drug administration (FDA) for desvenlafaxine succinate ...
Tags: Mylan, desvenlafaxine succinate extended-release tablets, MDD
-
H. Lundbeck Have Submitted a New Drug Application
Dec 5, 2012Takeda Pharmaceutical Company and H. Lundbeck have submitted a new drug application (NDA) to the FDA for vortioxetine (Lu AA21004), an investigational drug for the treatment of major depressive disorder (MDD). Vortioxetine is under ...
Tags: Takeda Pharmaceutical Company, major depressive disorder, MDD
-
Nectid Has Initiated Clinical Development of Agomelatine for Autism and Pain Indications
Nov 29, 2012Nectid, a drug discovery company, has initiated clinical development of agomelatine for autism and pain indications in the US. Agomelatine, a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is approved for the ...
-
Edgemont Pharmaceuticals Launched a Formulation Dose of Bupropion Extended-Release Tablets
Nov 29, 2012Edgemont Pharmaceuticals has launched a new formulation dose of bupropion extended-release tablets in a strength of 450mg dose. The Forfivo XL, which the company claims, is the only available 450mg dose of an extended-release bupropion ...
-
CE Mark Has Been Won by Neurosigma External Nerve Stimulation System
Sep 7, 2012NeuroSigma has obtained CE mark approval for its external Trigeminal Nerve Stimulation (eTNS) system, Monarch, designed for the treatment of epilepsy and major depressive disorder in adults and children of 9 years and older. The eTNS ...
Tags: NeuroSigma, eTNS, FDA
-
Eli Lilly Meets FDA Requirements for Pediatric Exclusivity for Cymbalta
Jul 9, 2012Eli Lilly and Company has met the United States Food and Drug Administration (FDA) requirements for pediatric exclusivity for Cymbalta (duloxetine HCl), which is available in 20-mg, 30-mg, and 60-mg capsules. As part of the approval, ...
